P38β MAP Kinase as a Therapeutic Target for Pancreatic Cancer

Chemical Biology and Drug Design

Volumn 80, Issue 2, 2012, Pages 266-273

  Singh, Abhay Kumar ^a   Pandey, Roshan ^a   Gill, Kamaldeep ^a   Singh, Ratnakar ^a   Saraya, Anoop ^a   Chauhan, Shyam S ^a   Yadav, Savita ^a   Pal, Sujoy ^a   Singh, Nidhi ^a   Dey, Sharmistha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytotoxicity; ELISA; Molecular marker; Pancreatic Cancer; Peptide Inhibitor; Surface Plasmon resonance

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 BETA; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG; VALINETRYPTOPHANCYSTEINESERINE;

ADULT; ARTICLE; BINDING SITE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DESIGN; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 11; MOLECULAR TARGETED THERAPY; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863994599     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01395.x     Document Type: Article

References (29)

1. Ansary-Moghaddam A., Huxley R., Barzi F., Lawes C., Ohkubo T., Fang X., Jee S.H., Woodward M. (2006) The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev;15:2435-2440.
2. Simeone D.M., Ji B., Banerjee M., Arumugam T., Li D., Anderson M.A., Bamberger A.M., Greenson J., Brand R.E., Ramachandran V., Logsdon C.D. (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas;34:436-443.
3. Satake K. (1991) Diagnosis of pancreatic cancer. Serological markers. Int J Pancreatol;9:93-98.
4. Hutter G., Sinha P. (2001) Proteomics for studying cancer cells and the development of chemoresistance. Proteomics;1:1233-1248.
5. Lohr M., Faissner R. (2004) Proteomics in pancreatic disease. Pancreatology;4:67-75.
6. Wulfkuhle J.D., Liotta L.A., Petricoin E.F. (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer;3:267-275.
7. Shekouh A.R., Thompson C.C., Prime W., Campbell F., Hamlett J., Herrington C.S., Lemoine N.R., Crnogorac-Jurcevic T., Buechler M.W., Friess H., Neoptolemos J.P., Pennington S.R., Costello E. (2003) Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics;3:1988-2001.
8. Dutta S.K., Girotra M., Singla M., Dutta A., Otis S.F., Nair P.P., Merchant N.B. (2011) Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas; online PMID:22158074.
9. Khoja L., Backen A., Sloane R., Menasce L., Ryder D., Krebs M., Board R., Clack G., Hughes A., Blackhall F., Valle J.W., Dive C. (2012) A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer;106:508-516.
10. Nebreda A.R., Porras A. (2000) p38 MAP kinases: beyond the stress response. Trends Biochem Sci;25:257-260.
11. Xiu M., Kim J., Sampson E., Huang C.Y., Davis R.J., Paulson K.E., Yee A.S. (2003) The transcriptional repressor HBP1 is a target of the p38 mitogen-activated protein kinase pathway in cell cycle regulation. Mol Cell Biol;23:8890-8901.
12. Olson C.M., Hedrick M.N., Izadi H., Bates T.C., Olivera E.R., Anguita J. (2007) p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens. Infect Immun;75:270-277.
13. Laemmli U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature;227:680-685.
14. Boussac M., Garin J. (2000) Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis;21:665-672.
15. Kinter M., Sherman N.E. (2000) Protein Sequencing and Identification Using Tandem Mass Spectrometry. John Wiley and Sons, Inc., Singapore.
16. Otto A. (1968) Excitation of nonradiative surface plasma waves in silver by the method of frustrated total reflection. Z Phys;216:398-410.
17. Kretschmann E., Reather H. (1968) Radiative decay of nonradiative surface Plasmon excited by light. Z Nature;23A:2135-2136.
18. Nylander C., Leidberg B., Lind T. (1982) Gas detection by means of surface plasmon resonance. Sens Actuators;3:79-88.
19. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keefe S.J., O'Neill E.A. (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry;37:13846-13853.
20. Bausch D., Thomas S., Mino-Kenudson M., Fernandez-del C.C., Bauer T.W., Williams M., Warshaw A.L., Thayer S.P., Kelly K.A. (2011) Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res;17:302-309.
21. Pedraza-Alva G., Koulnis M., Charland C., Thornton T., Clements J.L., Schlissel M.S., Rincon M. (2006) Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J;25:763-773.
22. Patel S.B., Cameron P.M., O'Keefe S.J., Frantz-Wattley B., Thompson J., O'Neill E.A., Tennis T., Liu L., Becker J.W., Scapin G. (2009) The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha. Acta Crystallogr D Biol Crystallogr;65:777-785.
23. Hill R.J., Dabbagh K., Phippard D., Li C., Suttmann R.T., Welch M., Papp E. et al. (2008) Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. JPET;327:610-619.
24. Nakao A., Ohkawa N., Nagasaki T., Kagari T., Doi H., Shimozato T., Ushiyama S., Aoki K. (2010) Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3. Bioorg Med Chem Lett;20:4774-4778.
25. Chopra P., Kulkarni O., Gupta S., Bajpai M., Kanoje V., Banerjee M., Bansal V., Visaga S., Chatterjee M., Chaira T., Shirumalla R.K., Verma A.K., Dastidar S.G., Sharma G., Ray A. (2010) Pharmacological profile of AW-814141, a novel, potent, selective and orally activeinhibitor of p38 MAP kinase. Int Immunopharmacol;10:467-473.
26. Trifilieff A., Keller T.H., Press N.J., Howe T., Gedeck P., Beer D., Walker C. (2005) CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol;144:1002-1010.
27. Ward K.W., Proksch J.W., Salyers K.L., Azzarano L.M., Morgan J.A., Roethke T.J., Mcsurdy-freed J.E., Levy M.A., Smith B.R. (2002) SB-242235, a selective inhibitor of p38 mitogen activated protein kinase. I: preclinical pharmacokinetics. Xenobiotica;32:221-233.
28. Lee J.C., Kassis S., Kumar S., Badger A., Adams J.L. (1999) p38 Mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther;82:389-397.
29. Nakao A., Ohkawa N., Nagasaki T., Kagari T., Doi H., Shimozato T., Ushiyama S., Aoki K. (2010) Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3. Bioorg Med Chem Lett;20:4774-4778.